经会阴与经直肠MRI-US融合穿刺检测前列腺癌准确性的非劣效自身对照研究
结果显示csPCa总检出32例(42%),TP-fusion检出全部32例而TR-fusion仅检出20例(26%),绝对差异15.6%(90%CI 27.9-3.2%)支持TP-fusion,TP-fusion非劣效且优效于TR-fusion。
要点
- TP-fusion对MRI可见指数病灶的csPCa检出率高于TR-fusion。
- TP-fusion检出全部32例csPCa,TR-fusion仅检出20例(26%)。
- 绝对差异15.6%(90%CI 27.9-3.2%)支持TP-fusion优效。
核心结论
- 在MRI可见指数病灶内检测csPCa时,TP-fusion非劣效且优效于TR-fusion。
研究设计与样本
- 同一会话内按随机顺序对优势指数病灶分别行TR-fusion和TP-fusion,每种途径取样4-6次并重置设备以避免偏倚。
主要发现
- csPCa共检出32例(42%),TP-fusion检出全部32例,TR-fusion仅检出20例(26%)。
- csPCa诊断绝对差异为15.6%(90%CI 27.9-3.2%),支持TP-fusion(p=0.029)。
- 探索性亚组分析显示TP-fusion在患者和指数病灶相关亚组中均与更高的csPCa检出率相关。
关键数值与推荐
- csPCa定义为Grade Group≥2或癌芯长度≥6 mm。
- 非劣效界值为10%,单侧α水平为5%。
- TP-fusion与TR-fusion之间90%置信区间下限大于零,故TP-fusion亦被判定为优效。
临床怎么用
- 在TP和TR-fusion均有经验的中心,选择穿刺方法时应考虑本研究结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Magnetic resonance imaging (MRI) and ultrasound (US) fusion prostate-biopsies can be performed in a transrectal (TR-fusion) or transperineal (TP-fusion) approach. Prospective comparative evidence is limited. In this study we compared the detection rate of clinically-significant prostate-cancer (csPCa) within an index lesion between TR and TP-fusion. PATIENTS AND METHODS: This was a prospective, noninferiority, and within-person trial. Men scheduled for MRI-US-fusion with a discrete MRI PI-RRAD ≥ 3 lesion were included. A dominant index lesion was determined for each subject and sampled by TR and TP-fusion during the same session. The order of biopsies was randomized and equipment was reset to avoid chronological and incorporation bias. For each subject, the index lesion was sampled 4-6 times in each approach. All biopsies were performed using Navigo fusion software (UC-Care, Yokneam, Israel). csPCa was defined as: Grade Group ≥ 2 or cancer-core length ≥ 6 mm. We used a noninferiority margin of 10% and a one-sided alpha level of 5%. RESULTS: Seventy-seven patients completed the protocol. Median age was 68.2 years (IQR:64.2-72.2), median PSA was 8.9 ng/ml (IQR:6.18-12.2). Ten patients (13%) were biopsy naive, others (87%) had a previous biopsy. csPCa was detected in 32 patients (42%). All of these cases were detected by TP-fusion, while only 20 (26%) by TR-fusion. Absolute difference for csPCa diagnosis was 15.6 (CI 90% 27.9-3.2%) in favor of TP-fusion (p = 0.029). TP-fusion was noninferior to TR-fusion. The lower boundary of the 90% confidence-interval between TP-fusion and TR-fusion was greater than zero, therefore TP-fusion was also found to be superior. Exploratory subgroup analyses showed TP-fusion was consistently associated with higher detection rates of csPCa compared with TR-fusion in patient and index-lesion derived subgroups (size, location, PI-RADS, PSA, and biopsy history). CONCLUSIONS: In this study, TP-fusion biopsies were found to be noninferior and superior to TR-fusion biopsies in detecting csPCa within MRI-visible index lesion. Centers experienced in both TP and TR-fusion should consider these results when choosing biopsy method.
引用
- Ber Y, Segal N, Tamir S, et al. A noninferiority within-person study comparing the accuracy of transperineal to transrectal MRI-US fusion biopsy for prostate-cancer detection. Prostate Cancer Prostatic Dis. 2020. PMID: 31953483. doi:10.1038/s41391-020-0205-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。